RC1416
/ RegeneCore Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
July 08, 2025
A Phase Ib Study of RC1416 Injection
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Nanjing RegeneCore Biotech Co., Ltd. | Not yet recruiting ➔ Recruiting | Initiation date: May 2025 ➔ Oct 2024
Enrollment open • Trial initiation date • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL13 • IL4 • IL5
April 07, 2025
A Phase Ib Study of RC1416 Injection
(clinicaltrials.gov)
- P1 | N=40 | Not yet recruiting | Sponsor: Nanjing RegeneCore Biotech Co., Ltd.
New P1 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases • IL13 • IL4 • IL5
December 02, 2024
A Phase I Study of RC1416 Injection
(clinicaltrials.gov)
- P1 | N=48 | Completed | Sponsor: Nanjing RegeneCore Biotech Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Aug 2024 ➔ May 2024
Trial completion • Trial completion date
October 05, 2023
A Phase I Study of RC1416 Injection
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: Nanjing RegeneCore Biotech Co., Ltd.
New P1 trial
1 to 4
Of
4
Go to page
1